Purdue partners with India's Dr. Reddy's Laboratories
July 27, 2015
WEST LAFAYETTE, Ind. — Purdue University has signed a strategic partnership memorandum of understanding with Dr. Reddy's Laboratories Limited (DRL), with headquarters in Hyderabad, India, to strengthen pharmaceutical research and development. The intent is to forge a strong strategic partnership in a range of research areas and novel technologies.
Dr. Reddy's Laboratories is a global pharmaceutical company that makes products across major therapeutic areas including gastrointestinal ailments, cardiovascular disease, pain management, oncology, anti-infectives, pediatrics and dermatology. DRL offers more than 200 generic versions of medicines in 26 countries around the world.
Suresh Garimella, Purdue executive vice president for research and partnerships, and his counterpart Amit Biswas, executive vice president and global head of integrated product development, signed a memorandum of understanding on June 22, between the two institutions that will advance the Purdue Moves drug discovery initiative to translate basic research into life-changing treatments.
"Purdue has tremendous strength in pharmaceutical drug discovery and development research, but we need additional partners to help translate our discoveries through to the delivery of a medicine or technology," Garimella said. "Dr. Reddy's Laboratories is a global pharmaceutical company that shares our mission to accelerate the rate at which new, advanced treatments make it to the millions of patients in need of relief. This partnership combines strengths that could lead to world-changing research."
The strategic partnership will focus on research in pharmaceutical processes and product development. Areas of planned collaborative research and education include targeted drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering, and research and development methodologies and technology. The collaboration will include student engagement and faculty exchanges and may include a site at Purdue Research Park.
Biswas said the long-term research partnership will help accelerate innovative drug development and manufacturing excellence.
"The long-term research partnership augurs well for DRL's philosophy of providing access to innovative, high-quality medicines to global patients at affordable cost," he said. "Purdue University has talented researchers, unique instrumentation and an interdisciplinary approach to solving technology challenges that make them a perfect partner as we sharpen our focus on innovative drug development programs. We are thrilled to partner with Purdue. Together we can find innovative solutions to address unmet needs and improve the health of people all over the world."
The strategic partnership follows a 2014 trip to India in which Purdue President Mitch Daniels met with several university and corporate partners and announced a Purdue Alumni Network in the country and an India-Purdue Collaborative Lecture series. R. Graham Cooks, Purdue's Henry Bohn Hass Distinguished Professor of Chemistry, and Chintamani Nagesa Ramachandra (C.N.R.) Rao, chairman of the Scientific Advisory Council to India's prime minister, spoke at the inaugural lecture series held in January 2015.
Daniels plans to visit India again in the fall to continue to strengthen Purdue's relationship with the country.
Close to 1,500 students from India are currently enrolled at Purdue, and thousands of Purdue alumni live in India. The university has the second-largest international student population among U.S. public universities and is third overall, according to the Institute of International Education in 2013-14. India has the second-highest number of international students at Purdue.
Purdue has several partnerships involving engineering, agriculture, business, science, technology, pharmacy, veterinary medicine, liberal arts and technology with institutions in India. The organizations include the Indian Institute of Technology Madras, the Indian Institute of Technology Hyderabad, and the Indian Council of Agricultural Research.
About Dr. Reddy's Laboratories Ltd.
Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines, because we believe that Good Health Can't Wait. Through our three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products, we offer a portfolio of products and services that include active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimillars and differentiated formulations. With operations in 26 countries across the globe, our major therapeutic areas are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. For more information, log on to: www.drreddys.com
Media Contact: Elizabeth K. Gardner, 765-494-2081, email@example.com
Source: Suresh Garimella, firstname.lastname@example.org
Related news releases: